Page 1

abbvie PRESS RELEASE AbbVie Reports First - Quarter 2021 Financial Results Reports First - Quarter Diluted EPS of $ 1.99 on a GAAP Basis ; Adjusted Diluted EPS of $ 2.95 Delivers First - Quarter Net Revenues of $ 13.010 Billion on a GAAP Basis , an Increase of 51.0 Percent on a Reported Basis ; Adjusted Net Revenues Were $ 12.935 Billion ● ● ● ● ● ● First - Quarter Global Net Revenues from the Immunology Portfolio Were $ 5.744 Billion , an Increase of 12.9 Percent on a Reported Basis , or 11.8 Percent on an Operational Basis ; U.S. Humira Net Revenues Were $ 3.907 Billion , an Increase of 6.9 Percent ; Internationally , Humira Net Revenues Were $ 960 Million , a Decrease of 8.3 Percent on a Reported Basis , or 12.6 Percent on an Operational Basis , Due to Biosimilar Competition ; Global Skyrizi Net Revenues Were $ 574 Million ; Global Rinvoq Net Revenues Were $ 303 Million First - Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $ 1.673 Billion , an Increase of 8.0 Percent on a Reported Basis , or 7.3 Percent on an Operational Basis ; Global Imbruvica Net Revenues Were $ 1.268 Billion , an Increase of 2.9 Percent , with U.S. Net Revenues of $ 999 Million and International Profit Sharing of $ 269 Million ; Global Venclexta Net Revenues Were $ 405 Million First - Quarter Global Net Revenues from the Aesthetics Portfolio Were $ 1.141 Billion ; Global Botox Cosmetic Net Revenues Were $ 477 Million First - Quarter Global Net Revenues from the Neuroscience Portfolio Were $ 1.248 Billion ; Global Botox Therapeutic Net Revenues Were $ 532 Million ; Global Vraylar Net Revenues Were $ 346 Million Raises 2021 GAAP Diluted EPS Guidance Range from $ 6.69 to $ 6.89 to $ 7.27 to $ 7.47 ; Raises 2021 Adjusted Diluted EPS Guidance Range from $ 12.32 to $ 12.52 to $ 12.37 to $ 12.57 NORTH CHICAGO , III . , April 30 , 2021 - AbbVie ( NYSE : ABBV ) announced financial results for the first quarter ended March 31 , 2021 . " We are off to an excellent start to 2021 , with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations , " said Richard A. Gonzalez , chairman and chief executive officer , AbbVie . " Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years - including five expected approvals in 2021. " Note : " Operational " comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates . 1